Exelixis Inc

EXEL Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of EXEL by members of U.S. Congress

Politician Type Traded
Ro Khanna House / D Sale $1,001 - $15,000 Jan 10, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Dec 06, 2022
Ro Khanna House / D Sale $1,001 - $15,000 Jan 08, 2020
Donna E. Shalala House / D Sale $1,001 - $15,000 Jun 04, 2019
Donna E. Shalala House / D Sale $1,001 - $15,000 Apr 16, 2019
Donna E. Shalala House / D Purchase $1,001 - $15,000 Feb 06, 2019
Donna E. Shalala House / D Purchase $1,001 - $15,000 Jan 09, 2019
Ro Khanna House / D Purchase $1,001 - $15,000 Oct 25, 2018
Ro Khanna House / D Sale $1,001 - $15,000 Jun 15, 2018
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 03, 2018
EXEL Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
EXEL Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
EXEL Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in EXEL holdings by institutional investors

Insider Trading

Quarterly net insider trading by EXEL's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $500,000 Oct 20, 2025 Issue: Health Issues Taxation/Internal Revenue Code
  • $480,000 Jul 21, 2025 Issue: Health Issues Taxation/Internal Revenue Code
  • $460,000 Apr 18, 2025 Issue: Health Issues Taxation/Internal Revenue Code
  • $460,000 Jan 21, 2025 Issue: Health Issues Taxation/Internal Revenue Code
  • $460,000 Oct 21, 2024 Issue: Taxation/Internal Revenue Code Health Issues
  • $460,000 Jul 22, 2024 Issue: Taxation/Internal Revenue Code Health Issues
  • $450,000 Apr 22, 2024 Issue: Taxation/Internal Revenue Code Health Issues
  • $450,000 Jan 19, 2024 Issue: Taxation/Internal Revenue Code Health Issues
  • $460,000 Oct 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $460,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $330,000 Jan 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $320,000 Oct 19, 2022 Issue: Taxation/Internal Revenue Code Health Issues
  • $300,000 Jul 19, 2022 Issue: Taxation/Internal Revenue Code Health Issues
  • $290,000 Apr 19, 2022 Issue: Health Issues
  • $280,000 Jan 19, 2022 Issue: HEALTH ISSUES
  • $230,000 Oct 20, 2021 Issue: HEALTH ISSUES
  • $220,000 Jul 20, 2021 Issue: HEALTH ISSUES
  • $220,000 Apr 19, 2021 Issue: HEALTH ISSUES
  • $220,000 Jan 20, 2021 Issue: HEALTH ISSUES
  • $240,000 Oct 20, 2020 Issue: HEALTH ISSUES
  • $240,000 Jul 20, 2020 Issue: HEALTH ISSUES
  • $220,000 Apr 20, 2020 Issue: HEALTH ISSUES
  • $190,000 Jan 21, 2020 Issue: HEALTH ISSUES
  • $180,000 Oct 21, 2019 Issue: Health Issues
  • $320,000 Jul 22, 2019 Issue: Health Issues
  • $300,000 Apr 22, 2019 Issue: Health Issues
  • $20,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues
  • $60,000 Jan 17, 2019 Issue: Health Issues
  • $60,000 Oct 09, 2018 Issue: Health Issues
  • $60,000 Jul 18, 2018 Issue: Health Issues
  • $50,000 Apr 19, 2018 Issue: Health Issues
Corporate Lobbying

EXEL Estimated quarterly lobbying spending

Revenue Breakdown

EXEL Revenue by Segment or Geography

By Segment
By Geography
EXEL Income Statement
EXEL Balance Sheet
EXEL Cash Flow
U.S. Patents

New EXEL patent grants

  • Patent Title: Process for preparing quinoline derivatives May. 15, 2018
  • Patent Title: Method of treating cancer Jan. 09, 2018
  • Patent Title: Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n′(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer Nov. 07, 2017
  • Patent Title: Process for making compounds for use in the treatment of cancer Sep. 26, 2017
  • Patent Title: C-met modulator pharmaceutical compositions Aug. 08, 2017
  • Patent Title: Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds Aug. 01, 2017
  • Patent Title: Inhibitors of pi3k-delta and methods of their use and manufacture Jun. 06, 2017
  • Patent Title: Process for preparing quinoline derivatives Jun. 14, 2016
  • Patent Title: Inhibitors of pi3k-delta and methods of their use and manufacture May. 24, 2016
  • Patent Title: Combinations of kinase inhibitors for the treatment of cancer Apr. 21, 2015
  • Patent Title: Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors Dec. 02, 2014
  • Patent Title: Phosphatidylinositol 3-kinase inhibitors and methods of their use Nov. 18, 2014
  • Patent Title: (l)-malate salt of n-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Nov. 04, 2014
  • Patent Title: Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents Aug. 12, 2014
  • Patent Title: Acetanilide sphingosine-1-phosphate receptor antagonists Jul. 29, 2014
  • Patent Title: Scds as modifiers of the p53 pathway and methods of use Jul. 08, 2014
  • Patent Title: Cdk9 as modifier of the igf pathway and methods of use Jun. 24, 2014
  • Patent Title: Quinazolinone modulators of nuclear receptors Jun. 10, 2014
  • Patent Title: Pyrazole kinase modulators and methods of use Apr. 29, 2014
  • Patent Title: Raf modulators and methods of use Apr. 15, 2014
  • Patent Title: Eef2k as modifiers of the pten/akt pathway and methods of use Mar. 25, 2014
  • Patent Title: Crystalline forms on n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Mar. 18, 2014
  • Patent Title: Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture Feb. 11, 2014
  • Patent Title: 1-phenylpyrrole derivatives Feb. 04, 2014
  • Patent Title: Method of using pi3k and mek modulators Feb. 04, 2014
  • Patent Title: Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture Jan. 28, 2014
  • Patent Title: Plks as modifiers of the beta catenin pathway and methods of use Jan. 21, 2014
  • Patent Title: Azepinoindole derivatives as pharmaceutical agents Sep. 03, 2013
  • Patent Title: Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha Aug. 20, 2013
  • Patent Title: C-met modulators and method of use Jul. 30, 2013
  • Patent Title: Atropisomers of (hydroxyalkyl) pyrrole derivatives Jul. 16, 2013
  • Patent Title: Pik4ca as modifier of the rac pathway and methods of use Jul. 09, 2013
  • Patent Title: Combination therapies comprising quinoxaline inhibitors of p13k-alpha for use in the treatment of cancer Jul. 09, 2013
  • Patent Title: C-met modulators and method of use Jul. 02, 2013
  • Patent Title: Azepine derivatives as pharmaceutical agents Jun. 18, 2013
  • Patent Title: Substituted pyrimidine compositions and methods of use Jun. 04, 2013
  • Patent Title: 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and methods of use May. 14, 2013
  • Patent Title: Rors as modifiers of the p21 pathway and methods of use Apr. 23, 2013
  • Patent Title: Pyrazolo pyrimidines as casein kinase ii (ck2) modulators Feb. 12, 2013
  • Patent Title: Pyrrole derivatives as pharmaceutical agents Feb. 05, 2013
  • Patent Title: C-kit modulators and methods of use Jan. 29, 2013
  • Patent Title: Azetidines as mek inhibitors for the treatment of proliferative diseases Jan. 29, 2013
  • Patent Title: Pyrimidinones as casein kinase ii (ck2) modulators Dec. 04, 2012
  • Patent Title: Pgds as modifiers of the pten pathway and methods of use Oct. 16, 2012
  • Patent Title: Marks as modifers of the pten pathway and methods of use Sep. 25, 2012
  • Patent Title: Map3ks as modifiers of the p53 pathway and methods of use Sep. 18, 2012
  • Patent Title: Pyridopyrimidinone inhibitors of pi3kα for the treatment of cancer Aug. 21, 2012
  • Patent Title: 6-phenylpyrimidinones as pim modulators Aug. 14, 2012
  • Patent Title: Methods of using igfir and abl kinase modulators Jul. 17, 2012
  • Patent Title: Pyrimidine derivatives as kinase modulators and method of use Jul. 03, 2012
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to EXEL from public contracts

EXEL News

Recent insights relating to EXEL

CNBC Recommendations

Recent picks made for EXEL stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in EXEL

EXEL Analyst Ratings

EXEL Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
EXEL Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $EXEL stock a Buy, Sell, or Hold?

  • What is the price target for $EXEL stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

EXEL Top Shareholders
Shareholder
Shares Held
EXEL Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $EXEL stock?

  • Who owns the most shares of $EXEL stock?

  • What funds own $EXEL stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

EXEL Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view EXEL Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About EXEL

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

  • Address Alameda, CA
  • Market Cap 11.4 billion
  • Employees 1,147
  • Industrial Classification Biological Products, (No Disgnostic Substances)
Back To Top